iDiabetes platform—enhanced phenotyping of patients with diabetes for precision diagnosis, prognosis and treatment: study protocol for a cluster-randomised controlled study in Tayside, Scotland
Authors:
- YeunYi LinYLYeunYi Lin
- Damien LeithDLDamien Leith
- Michael AbbottMAMichael Abbott
- Rachael BarrettRBRachael Barrett
- Samira BellSBSamira Bell
- Tim J CroudaceTCTim J Croudace
- Scott CunninghamSCScott Cunningham
- John DillonJDJohn Dillon
- Peter DonnanPDPeter Donnan
- Albert FarreAlbert Farre
- Rodolfo HernándezRHRodolfo Hernández
- Chim LangCLChim Lang
Open Access
Abstract
Introduction and aim: Diabetes is a global health emergency with increasing prevalence and diabetes-associated morbidity and mortality. One of the challenges in optimising diabetes care is translating research advances in this heterogeneous disease into clinical care. A potential solution is the introduction of precision medicine approaches into diabetes care. We aim to develop a digital platform called ‘intelligent Diabetes’ (iDiabetes) to support a precision diabetes care model in Scotland and assess its impact on the primary composite outcome of all-cause mortality, hospitalisation rate, renal function decline and glycaemic control. Methods and analysis: The impact of iDiabetes will be evaluated through a cluster-randomised controlled study, recruiting up to 22 500 patients with diabetes. Primary care general practices (GPs) in the National Health Service (NHS) Scotland Tayside Health Board are the units (clusters) of randomisation. Each primary care GP will form one cluster (approximately 400 patients per cluster), with up to 60 clusters recruited. Randomisation will be to iDiabetes (guideline support ), iDiabetesPlus or usual diabetes care (control arm). Patients of participating primary care GPs are automatically enrolled on the study when they attend for their annual diabetes screening or are newly diagnosed with diabetes. A composite hierarchical primary outcome, evaluated using Win-Ratio statistical methodology, will consist of (1) all-cause mortality, (2) all-cause hospitalisation rate, (3) proportion with >40% estimated glomerular filtration rate [eGFR] reduction from baseline or new development of end-stage renal disease, (4) proportion with absolute HbA1C reduction >0.5%. Outcomes will be evaluated after a 2-year median follow-up period. Comprehensive qualitative and health economic analyses will be conducted, assessing the cost-effectiveness, budget impact and user acceptability of the iDiabetes platform. Ethics and dissemination: This study was reviewed by the NHS Health Research Authority and approved by the East of Scotland Research Ethics Committee (reference: 23/ES/0008). Study findings will be disseminated via publications, presented at scientific conferences and shared with patients and the public on the study website and social media. Trial registration number: ISRCTN18000901 .Keywords
All Related Versions
Funding Information
- Chief Scientist Office (PMAS-21-01)
This publication has 21 references indexed in Scilit:
- Painting a new picture of personalised medicine for diabetesDiabetologia, 2017
- Code Saturation Versus Meaning SaturationQualitative Health Research, 2016
- Validation of the UKPDS 82 risk equations within the Cardiff Diabetes ModelCost Effectiveness and Resource Allocation, 2015
- Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase MutationDiabetes Care, 2015
- Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy ModelDiabetic Medicine, 2014
- What is an adequate sample size? Operationalising data saturation for theory-based interview studiesPsychology & Health, 2010
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- Discrete choice experiments in health careBMJ, 2004
- Validation of the CORE Diabetes Model Against Epidemiological and Clinical StudiesCurrent Medical Research and Opinion, 2004
- Genetic cause of hyperglycaemia and response to treatment in diabetesThe Lancet, 2003